A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis

Cancer Science

Volumn 103, Issue 5, 2012, Pages 939-944

  Awazu, Yoshiko ^a   Mizutani, Akio ^a   Nagase, Yoshinori ^b   Iwata, Hidehisa ^c   Oguro, Yuya ^a   Miki, Hiroshi ^c   Imamura, Shinichi ^a   Hori, Akira ^a  

^a Oncology Drug Discovery Unit   (Japan)

^b Strategic Product Planning Department   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IRINOTECAN; N [2 FLUORO 4 [(5 METHYL 5H PYRROLO[3,2 D]PYRIMIDIN 4 YL)OXY]PHENYL] N [3 (TRIFLUOROMETHYL)PHENYL]UREA; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; MICROVASCULATURE; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; TISSUE PRESSURE; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; PHENYLUREA COMPOUNDS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860243550     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02238.x     Document Type: Article

References (24)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
4. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
6. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
7. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003; 130: 4769-84.
8. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004; 15: 215-28.
9. Oguro Y, Miyamoto N, Okada K et al. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3, 2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem 2010; 18: 7260-73.
10. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-40.
11. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
12. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006; 94: 1355-60.
13. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-58.
14. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
15. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67: 2729-35.
16. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-86.
17. Lee CG, Heijn M, di Tomaso E et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565-70.
18. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-6.
19. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
22. Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929-34.
23. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-84.
24. Pietras K, Stumm M, Hubert M et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9: 3779-87.